We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Smart Pills Offer Diagnostic Tool for Gut Disorders

By LabMedica International staff writers
Posted on 08 May 2017
Researchers have completed successful phase-one human clinical trials of ingestible capsules (the size of a vitamin pill) that have potential to revolutionize diagnosis and prevention of gastrointestinal (GI) disorders and diseases.

Researchers at RMIT University (Melbourne, Australia), led by the pills’ co-inventor Prof. More...
Kourosh Kalantar-zadeh, tested the ingestible smart capsules that journey through and measure gas levels in the GI tract. The human trials were undertaken with colleagues from Monash University. “We have been lucky to have Monash medical academics helping us on this journey,” said Prof. Kalantar-zadeh, “Without their input we would not be able to proceed.”

RMIT is one of the leading universities researching the development of ingestible sensors, a technology that has demonstrated several 1000s-times more sensitivity to gut gases than current alternative techniques. “Currently, one of the only methods for diagnosing gut disorders, such as mal-absorption of carbohydrates, irritable bowel syndrome, and inflammable bowel disease, is to measure hydrogen concentrations in the breath,” said Prof. Kalantar-zadeh, “However, breath tests are mired by a lack of sensitivity and specificity and are unable to provide the necessary gold standard for diagnosis.”

Co-inventor Dr. Kyle Berean said, “Ingestible sensors also offer a reliable diagnostic tool for colon cancer, meaning that people won’t have to undergo colonoscopies in future.”

A key finding from the initial trials was on the safety of the new technology: “Smart pills are harmless and there is no risk of capsule retention,” said Dr. Berean. An added advantage is that the capsules can be synched with smartphones, meaning results are easily accessible by users and doctors online. There are also many potential applications for this technology.

“The sensors allow us to measure all the fluids and gases in the gut, giving us a multidimensional picture of the human body,” said Prof. Kalantar-zadeh, “Gas sensing is just the beginning.”

A paper by the Centre for Advanced Electronics and Sensors (CADES) research team outlining the future of ingestible sensors was published in the April 2017 issue of the journal ACS Sensors. Outcomes of the human trials were presented at Digestive Disease Week (DDW; Chicago, IL, USA, May 6-9, 2017).


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Automated Urinalysis Solution
UN-9000
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Industry

view channel
Image Credit: Adobe Stock

Mayo Clinic and Thermo Fisher Launch Multi-Omics Venture to Identify Early Disease Signals

Many diseases begin developing years before symptoms emerge, making early detection difficult for healthcare systems and clinical laboratories. Linking molecular changes with longitudinal health data could... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.